These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 23843149)
21. Crystal structure of the p38α MAP kinase in complex with a docking peptide from TAB1. Xin F; Wu J Sci China Life Sci; 2013 Jul; 56(7):653-60. PubMed ID: 23722236 [TBL] [Abstract][Full Text] [Related]
22. Exploring protein kinase conformation using swarm-enhanced sampling molecular dynamics. Atzori A; Bruce NJ; Burusco KK; Wroblowski B; Bonnet P; Bryce RA J Chem Inf Model; 2014 Oct; 54(10):2764-75. PubMed ID: 25178116 [TBL] [Abstract][Full Text] [Related]
23. Rapid identification of ligand-binding sites by using an assignment-free NMR approach. Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460 [TBL] [Abstract][Full Text] [Related]
24. Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Bührmann M; Hardick J; Weisner J; Quambusch L; Rauh D Angew Chem Int Ed Engl; 2017 Oct; 56(43):13232-13236. PubMed ID: 28834017 [TBL] [Abstract][Full Text] [Related]
25. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids. Goettert M; Schattel V; Koch P; Merfort I; Laufer S Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268 [TBL] [Abstract][Full Text] [Related]
26. Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α. Roser P; Weisner J; Simard JR; Rauh D; Drescher M Chem Commun (Camb); 2018 Oct; 54(85):12057-12060. PubMed ID: 30295691 [TBL] [Abstract][Full Text] [Related]
27. Active mutants of the TCR-mediated p38α alternative activation site show changes in the phosphorylation lip and DEF site formation. Tzarum N; Diskin R; Engelberg D; Livnah O J Mol Biol; 2011 Feb; 405(5):1154-69. PubMed ID: 21146537 [TBL] [Abstract][Full Text] [Related]
28. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957 [TBL] [Abstract][Full Text] [Related]
29. Probing invisible, low-populated States of protein molecules by relaxation dispersion NMR spectroscopy: an application to protein folding. Korzhnev DM; Kay LE Acc Chem Res; 2008 Mar; 41(3):442-51. PubMed ID: 18275162 [TBL] [Abstract][Full Text] [Related]
31. Three-dimensional docking in the MAPK p38α. Goldsmith EJ Sci Signal; 2011 Dec; 4(204):pe47. PubMed ID: 22375047 [TBL] [Abstract][Full Text] [Related]
32. p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Nishida K; Yamaguchi O; Hirotani S; Hikoso S; Higuchi Y; Watanabe T; Takeda T; Osuka S; Morita T; Kondoh G; Uno Y; Kashiwase K; Taniike M; Nakai A; Matsumura Y; Miyazaki J; Sudo T; Hongo K; Kusakari Y; Kurihara S; Chien KR; Takeda J; Hori M; Otsu K Mol Cell Biol; 2004 Dec; 24(24):10611-20. PubMed ID: 15572667 [TBL] [Abstract][Full Text] [Related]
33. High-resolution diffracting crystals of intrinsically active p38alpha MAP kinase: a case study for low-throughput approaches. Diskin R; Engelberg D; Livnah O Acta Crystallogr D Biol Crystallogr; 2007 Feb; 63(Pt 2):260-5. PubMed ID: 17242519 [TBL] [Abstract][Full Text] [Related]
34. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode. Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475 [TBL] [Abstract][Full Text] [Related]
35. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors. Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496 [TBL] [Abstract][Full Text] [Related]
36. Structure-based 3D-QSAR models and dynamics analysis of novel N-benzyl pyridinone as p38α MAP kinase inhibitors for anticytokine activity. Ul-Haq Z; Khan W; Zia SR; Iqbal S J Mol Graph Model; 2012 Jun; 36():48-61. PubMed ID: 22534481 [TBL] [Abstract][Full Text] [Related]
37. Ligand binding promiscuity of human liver fatty acid binding protein: structural and dynamic insights from an interaction study with glycocholate and oleate. Favretto F; Assfalg M; Gallo M; Cicero DO; D'Onofrio M; Molinari H Chembiochem; 2013 Sep; 14(14):1807-19. PubMed ID: 23757005 [TBL] [Abstract][Full Text] [Related]
38. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487 [TBL] [Abstract][Full Text] [Related]
39. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287 [TBL] [Abstract][Full Text] [Related]
40. p38α MAP kinase phosphorylates RCAN1 and regulates its interaction with calcineurin. Ma L; Tang H; Ren Y; Deng H; Wu J; Wang Z Sci China Life Sci; 2012 Jul; 55(7):559-66. PubMed ID: 22864830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]